CN201701511U - 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 - Google Patents
装有阿莫西林片和盐酸氨溴索片的片剂胶囊 Download PDFInfo
- Publication number
- CN201701511U CN201701511U CN2010202421727U CN201020242172U CN201701511U CN 201701511 U CN201701511 U CN 201701511U CN 2010202421727 U CN2010202421727 U CN 2010202421727U CN 201020242172 U CN201020242172 U CN 201020242172U CN 201701511 U CN201701511 U CN 201701511U
- Authority
- CN
- China
- Prior art keywords
- capsule
- tablet
- amoxicillin
- ambroxol hydrochloride
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 66
- 229960003022 amoxicillin Drugs 0.000 title claims abstract description 53
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 53
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims abstract description 52
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 32
- 239000003086 colorant Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 7
- 239000006227 byproduct Substances 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 5
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 description 15
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940086793 amoxicillin 250 mg Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- -1 amino 3.5-dibromo-benzyl Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229960002793 amoxicillin sodium Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实施例1 | ||
0天含量 | 氨溴索(%) | 99.11 |
阿莫西林(%) | 99.57 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.01 | |
阿莫西林聚合物 | 0.06 |
5天含量 | 氨溴索(%) | 99.24 |
阿莫西林(%) | 99.32 | |
5天有关物 | N-A873CL | 0.02 |
N-AB773XX | 0.02 | |
阿莫西林聚合物 | 0.07 | |
10天含量 | 氨溴索(%) | 99.30 |
阿莫西林(%) | 99.26 | |
10天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.03 | |
阿莫西林聚合物 | 0.07 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.11 |
阿莫西林(%) | 99.57 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.01 | |
阿莫西林聚合物 | 0.06 | |
5天含量 | 氨溴索(%) | 99.21 |
阿莫西林(%) | 99.12 | |
5天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.01 | |
阿莫西林聚合物 | 0.06 |
10天含量 | 氨溴索(%) | 99.28 |
阿莫西林(%) | 99.16 | |
10天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.04 | |
阿莫西林聚合物 | 0.09 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.11 |
阿莫西林(%) | 99.57 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.01 | |
阿莫西林聚合物 | 0.06 | |
5天含量 | 氨溴索(%) | 99.34 |
阿莫西林(%) | 99.36 | |
5天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.03 | |
阿莫西林聚合物 | 0.07 | |
10天含量 | 氨溴索(%) | 99.36 |
阿莫西林(%) | 99.29 | |
10天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.04 | |
阿莫西林聚合物 | 0.09 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010202421727U CN201701511U (zh) | 2010-06-30 | 2010-06-30 | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010202421727U CN201701511U (zh) | 2010-06-30 | 2010-06-30 | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN201701511U true CN201701511U (zh) | 2011-01-12 |
Family
ID=43438654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010202421727U Expired - Fee Related CN201701511U (zh) | 2010-06-30 | 2010-06-30 | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN201701511U (zh) |
-
2010
- 2010-06-30 CN CN2010202421727U patent/CN201701511U/zh not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pogue et al. | Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing | |
Sandercock et al. | A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial | |
CN100358518C (zh) | 含特比萘芬的药物组合物及其应用 | |
CN201701513U (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN201701511U (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN102008467A (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN102008478A (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
US20220133717A1 (en) | Rabeximod in the treatment of rheumatoid arthritis | |
CN102018694A (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
CN201701514U (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN201701510U (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
CN201701512U (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN107913259A (zh) | 一种盐酸二甲双胍控释片及其制备方法 | |
CN102018709A (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN102018719A (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN202010289U (zh) | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 | |
CN202146449U (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN102274231A (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN202168960U (zh) | 含有奥美沙坦酯、氨氯地平和氢氯噻嗪的复方制剂 | |
CN101700237A (zh) | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 | |
Noh et al. | A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of two formulations of metformin in healthy volunteers | |
CN201524269U (zh) | 装有瑞拉格脲固体制剂和二甲双胍固体制剂的组合胶囊 | |
CN202568930U (zh) | 装有瑞格列奈固体制剂和二甲双胍固体制剂的片剂胶囊 | |
CN102871993A (zh) | 苦精的新用途 | |
CN202568926U (zh) | 装有阿格列汀固体制剂和吡格列酮固体制剂的片剂胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG FUHE HUAXING PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: WU GUANGYAN Effective date: 20110518 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, HEILONGJIANG, SUIHUA CITY, HEILONGJIANG PROVINCE TO: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, HEILONGJIANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110518 Address after: 151100 Heilongjiang Zhaodong Taiping Road 34, Heilongjiang Dilong pharmaceutical Limited by Share Ltd Patentee after: Heilongjiang Fuhe Huaxing Pharmaceutical Group Co., Ltd. Address before: Taiping Road Heilongjiang 151100 Zhaodong city of Heilongjiang province Suihua City, No. 34 Heilongjiang Dilong pharmaceutical Limited by Share Ltd Patentee before: Wu Guangyan |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110112 Termination date: 20160630 |